Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Genome-Wide Analysis of Interchromosomal Interaction Probabilities Reveals Chained Translocations and Overrepresentation of Translocation Breakpoints in Genes in a Cutaneous T-Cell Lymphoma Cell Line.

Steininger A, Ebert G, Becker BV, Assaf C, Möbs M, Schmidt CA, Grabarczyk P, Jensen LR, Przybylski GK, Port M, Kuss AW, Ullmann R.

Front Oncol. 2018 May 30;8:183. doi: 10.3389/fonc.2018.00183. eCollection 2018.

2.

Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model.

Benten D, Behrang Y, Unrau L, Weissmann V, Wolters-Eisfeld G, Burdak-Rothkamm S, Stahl FR, Anlauf M, Grabowski P, Möbs M, Dieckhoff J, Sipos B, Fahl M, Eggers C, Perez D, Bockhorn M, Izbicki JR, Lohse AW, Schrader J.

Mol Cancer Res. 2018 Mar;16(3):496-507. doi: 10.1158/1541-7786.MCR-17-0163. Epub 2018 Jan 12.

PMID:
29330294
3.

Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell lung cancer.

Taromi S, Lewens F, Arsenic R, Sedding D, Sänger J, Kunze A, Möbs M, Benecke J, Freitag H, Christen F, Kaemmerer D, Lupp A, Heilmann M, Lammert H, Schneider CP, Richter K, Hummel M, Siegmund B, Burger M, Briest F, Grabowski P.

Oncotarget. 2017 Sep 23;8(57):97061-97078. doi: 10.18632/oncotarget.21221. eCollection 2017 Nov 14.

4.

Mechanisms of Targeting the MDM2-p53-FOXM1 Axis in Well-Differentiated Intestinal Neuroendocrine Tumors.

Briest F, Grass I, Sedding D, Möbs M, Christen F, Benecke J, Fuchs K, Mende S, Kaemmerer D, Sänger J, Kunze A, Geisler C, Freitag H, Lewens F, Worpenberg L, Iwaszkiewicz S, Siegmund B, Walther W, Hummel M, Grabowski P.

Neuroendocrinology. 2018;107(1):1-23. doi: 10.1159/000481506. Epub 2017 Sep 14.

PMID:
28910819
5.

The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models.

Nölting S, Rentsch J, Freitag H, Detjen K, Briest F, Möbs M, Weissmann V, Siegmund B, Auernhammer CJ, Aristizabal Prada ET, Lauseker M, Grossman A, Exner S, Fischer C, Grötzinger C, Schrader J, Grabowski P; GERMAN NET-Z study group.

PLoS One. 2017 Aug 11;12(8):e0182852. doi: 10.1371/journal.pone.0182852. eCollection 2017.

6.

IL-32 induces indoleamine 2,3-dioxygenase+CD1c+ dendritic cells and indoleamine 2,3-dioxygenase+CD163+ macrophages: Relevance to mycosis fungoides progression.

Ohmatsu H, Humme D, Gonzalez J, Gulati N, Möbs M, Sterry W, Krueger JG.

Oncoimmunology. 2016 May 5;6(2):e1181237. doi: 10.1080/2162402X.2016.1181237. eCollection 2017.

7.

DNA copy number changes define spatial patterns of heterogeneity in colorectal cancer.

Mamlouk S, Childs LH, Aust D, Heim D, Melching F, Oliveira C, Wolf T, Durek P, Schumacher D, Bläker H, von Winterfeld M, Gastl B, Möhr K, Menne A, Zeugner S, Redmer T, Lenze D, Tierling S, Möbs M, Weichert W, Folprecht G, Blanc E, Beule D, Schäfer R, Morkel M, Klauschen F, Leser U, Sers C.

Nat Commun. 2017 Jan 25;8:14093. doi: 10.1038/ncomms14093.

8.

Inactivation of RUNX3/p46 Promotes Cutaneous T-Cell Lymphoma.

Haider A, Steininger A, Ullmann R, Hummel M, Dimitrova L, Beyer M, Vandersee S, Lenze D, Sterry W, Assaf C, Möbs M.

J Invest Dermatol. 2016 Nov;136(11):2287-2296. doi: 10.1016/j.jid.2016.05.126. Epub 2016 Jul 1.

9.

Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.

Darb-Esfahani S, Denkert C, Stenzinger A, Salat C, Sinn B, Schem C, Endris V, Klare P, Schmitt W, Blohmer JU, Weichert W, Möbs M, Tesch H, Kümmel S, Sinn P, Jackisch C, Dietel M, Reimer T, Loi S, Untch M, von Minckwitz G, Nekljudova V, Loibl S.

Oncotarget. 2016 Oct 18;7(42):67686-67698. doi: 10.18632/oncotarget.11891.

10.

Dimethyl fumarate restores apoptosis sensitivity and inhibits tumor growth and metastasis in CTCL by targeting NF-κB.

Nicolay JP, Müller-Decker K, Schroeder A, Brechmann M, Möbs M, Géraud C, Assaf C, Goerdt S, Krammer PH, Gülow K.

Blood. 2016 Aug 11;128(6):805-15. doi: 10.1182/blood-2016-01-694117. Epub 2016 Jun 6.

11.

NGS-based BRCA1/2 mutation testing of high-grade serous ovarian cancer tissue: results and conclusions of the first international round robin trial.

Endris V, Stenzinger A, Pfarr N, Penzel R, Möbs M, Lenze D, Darb-Esfahani S, Hummel M, Sabine-Merkelbach-Bruse, Jung A, Lehmann U, Kreipe H, Kirchner T, Büttner R, Jochum W, Höfler G, Dietel M, Weichert W, Schirmacher P.

Virchows Arch. 2016 Jun;468(6):697-705. doi: 10.1007/s00428-016-1919-8. Epub 2016 Mar 22.

PMID:
27003155
12.

The Effects of Arsenic Trioxide in Combination with Retinoic Acids on Cutaneous T-Cell Lymphoma Cell Lines.

Beyer M, Vandersee S, Cosagarea I, Touba R, Möbs M, Assaf C.

Skin Pharmacol Physiol. 2016;29(2):63-70. doi: 10.1159/000443840. Epub 2016 Mar 23.

13.

Multicenter Evaluation of a Novel Automated Rapid Detection System of BRAF Status in Formalin-Fixed, Paraffin-Embedded Tissues.

Schiefer AI, Parlow L, Gabler L, Mesteri I, Koperek O, von Deimling A, Streubel B, Preusser M, Lehmann A, Kellner U, Pauwels P, Lambin S, Dietel M, Hummel M, Klauschen F, Birner P, Möbs M.

J Mol Diagn. 2016 May;18(3):370-377. doi: 10.1016/j.jmoldx.2015.12.005. Epub 2016 Feb 24.

PMID:
26921540
14.

Aurora Kinase A Is Upregulated in Cutaneous T-Cell Lymphoma and Represents a Potential Therapeutic Target.

Humme D, Haider A, Möbs M, Mitsui H, Suárez-Fariñas M, Ohmatsu H, Isabell Geilen C, Eberle J, Krueger JG, Beyer M, Hummel M, Anagnostopoulos I, Sterry W, Assaf C.

J Invest Dermatol. 2015 Sep;135(9):2292-2300. doi: 10.1038/jid.2015.139. Epub 2015 Apr 7.

15.

Evaluation of blood parameters for the monitoring of erythrodermic cutaneous T-cell lymphoma.

Vandersee S, Humme D, Terhorst D, Almohamad A, Möbs M, Beyer M.

J Dtsch Dermatol Ges. 2015 Jan;13(1):30-6. doi: 10.1111/ddg.12549. English, German. Erratum in: J Dtsch Dermatol Ges. 2015 May;13(5):490.

PMID:
25640490
16.

Analysis of the IL-31 pathway in Mycosis fungoides and Sézary syndrome.

Möbs M, Gryzik S, Haidar A, Humme D, Beyer M, Vandersee S.

Arch Dermatol Res. 2015 Aug;307(6):479-85. doi: 10.1007/s00403-014-1527-x. Epub 2014 Dec 7.

PMID:
25488078
17.

IL32 is progressively expressed in mycosis fungoides independent of helper T-cell 2 and helper T-cell 9 polarization.

Ohmatsu H, Humme D, Gulati N, Gonzalez J, Möbs M, Suárez-Fariñas M, Cardinale I, Mitsui H, Guttman-Yassky E, Sterry W, Krueger JG.

Cancer Immunol Res. 2014 Sep;2(9):890-900. doi: 10.1158/2326-6066.CIR-13-0199-T. Epub 2014 Jun 17.

18.

T-cell receptor gene rearrangement analysis of sequential biopsies in cutaneous T-cell lymphomas with the Biomed-2 PCR reveals transient T-cell clones in addition to the tumor clone.

Humme D, Lukowsky A, Gierisch M, Haider A, Vandersee S, Assaf C, Sterry W, Möbs M, Beyer M.

Exp Dermatol. 2014 Jul;23(7):504-8. doi: 10.1111/exd.12453.

PMID:
24862432
19.

Molecular diagnostics in cutaneous lymphomas.

Möbs M, Cerroni L, Flaig MJ, Lenze D, Hummel M, Assaf C.

J Dtsch Dermatol Ges. 2013 May;11 Suppl 4:25-35. doi: 10.1111/ddg.12084_supp. No abstract available.

PMID:
23721639
20.

Identification of multiple complex rearrangements associated with deletions in the 6q23-27 region in Sézary syndrome.

Iżykowska K, Zawada M, Nowicka K, Grabarczyk P, Braun FCM, Delin M, Möbs M, Beyer M, Sterry W, Schmidt CA, Przybylski GK.

J Invest Dermatol. 2013 Nov;133(11):2617-2625. doi: 10.1038/jid.2013.188. Epub 2013 Apr 18. Erratum in: J Invest Dermatol. 2014 Feb;134(2):583.

21.

Allogeneic partially HLA-matched dendritic cells pulsed with autologous tumor cell lysate as a vaccine in metastatic renal cell cancer: a clinical phase I/II study.

Flörcken A, Kopp J, van Lessen A, Movassaghi K, Takvorian A, Jöhrens K, Möbs M, Schönemann C, Sawitzki B, Egerer K, Dörken B, Pezzutto A, Westermann J.

Hum Vaccin Immunother. 2013 Jun;9(6):1217-27. doi: 10.4161/hv.24149. Epub 2013 Mar 4.

22.

Apoptosis induction by SAHA in cutaneous T-cell lymphoma cells is related to downregulation of c-FLIP and enhanced TRAIL signaling.

Al-Yacoub N, Fecker LF, Möbs M, Plötz M, Braun FK, Sterry W, Eberle J.

J Invest Dermatol. 2012 Sep;132(9):2263-74. doi: 10.1038/jid.2012.125. Epub 2012 May 3.

23.

[Cutaneous malignant lymphomas. Update on diagnosis and therapy of cutaneous T-cell lymphomas].

Humme D, Möbs M, Pullmann S, Haidar A, Beyer M, Sterry W, Assaf C.

Hautarzt. 2012 May;63(5):423-35; quiz 436. doi: 10.1007/s00105-012-2387-y. German.

PMID:
22527299
24.

The tumour suppressor p53 is frequently nonfunctional in Sézary syndrome.

Lamprecht B, Kreher S, Möbs M, Sterry W, Dörken B, Janz M, Assaf C, Mathas S.

Br J Dermatol. 2012 Aug;167(2):240-6. doi: 10.1111/j.1365-2133.2012.10918.x. Epub 2012 Jun 6.

PMID:
22384858
25.

Nonsteroidal anti-inflammatory drugs induce apoptosis in cutaneous T-cell lymphoma cells and enhance their sensitivity for TNF-related apoptosis-inducing ligand.

Braun FK, Al-Yacoub N, Plötz M, Möbs M, Sterry W, Eberle J.

J Invest Dermatol. 2012 Feb;132(2):429-39. doi: 10.1038/jid.2011.316. Epub 2011 Oct 20.

26.

Genomic loss of the putative tumor suppressor gene E2A in human lymphoma.

Steininger A, Möbs M, Ullmann R, Köchert K, Kreher S, Lamprecht B, Anagnostopoulos I, Hummel M, Richter J, Beyer M, Janz M, Klemke CD, Stein H, Dörken B, Sterry W, Schrock E, Mathas S, Assaf C.

J Exp Med. 2011 Aug 1;208(8):1585-93. doi: 10.1084/jem.20101785. Epub 2011 Jul 25.

27.

Tumor suppressor TNFAIP3 (A20) is frequently deleted in Sézary syndrome.

Braun FC, Grabarczyk P, Möbs M, Braun FK, Eberle J, Beyer M, Sterry W, Busse F, Schröder J, Delin M, Przybylski GK, Schmidt CA.

Leukemia. 2011 Sep;25(9):1494-501. doi: 10.1038/leu.2011.101. Epub 2011 May 31.

PMID:
21625233
28.

Pathogenesis of Mycosis fungoides.

Beyer M, Möbs M, Humme D, Sterry W.

J Dtsch Dermatol Ges. 2011 Aug;9(8):594-8. doi: 10.1111/j.1610-0387.2011.07635.x. Epub 2011 Mar 3. Review. English, German.

PMID:
21371258
29.

Evaluation of T-cell clonality in archival skin biopsy samples of cutaneous T-cell lymphomas using the biomed-2 PCR protocol.

Lukowsky A, Muche JM, Möbs M, Assaf C, Humme D, Hummel M, Sterry W, Steinhoff M.

Diagn Mol Pathol. 2010 Jun;19(2):70-7. doi: 10.1097/PDM.0b013e3181b2a1b7.

PMID:
20502183
30.

Diagnostic tools in Sezary syndrome.

Möbs M, Knott M, Fritzen B, Pullmann S, Sterry W, Assaf C.

G Ital Dermatol Venereol. 2010 Jun;145(3):385-91. Review.

PMID:
20461046
31.

Zanolimumab, a human monoclonal antibody targeting CD4 in the treatment of mycosis fungoides and Sézary syndrome.

Mestel DS, Beyer M, Möbs M, Steinhoff M, Sterry W, Assaf C.

Expert Opin Biol Ther. 2008 Dec;8(12):1929-39. doi: 10.1517/14712590802528696 . Review.

PMID:
18990079
32.

T helper cell-mediated interferon-gamma expression after human parvovirus B19 infection: persisting VP2-specific and transient VP1u-specific activity.

Franssila R, Auramo J, Modrow S, Möbs M, Oker-Blom C, Käpylä P, Söderlund-Venermo M, Hedman K.

Clin Exp Immunol. 2005 Oct;142(1):53-61.

Supplemental Content

Support Center